

Amendments to the Claims:

Please amend claims 1, 2, 19, 26, 53, 54 and 56 and cancel claims 5, 3-18, 20-25, 27-52 and 57-80 without prejudice.

This listing of claims will replace all prior versions, and listings, of claims in the application.

In the Claims:

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises:

- a) a therapeutically effective amount of an ~~ECM binding extracellular matrix-binding~~ fragment of Ang-1 protein ~~that comprises selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and/or and SEQ ID NO:4, or a homologous peptide thereof~~ and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes an ~~ECM binding extracellular matrix-binding~~ fragment of Ang-1 protein ~~that comprises selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and/or and SEQ ID NO:4, or a homologous peptide thereof~~;
- b) a therapeutically effective amount of a ~~non ECM binding fragment of Ang-1 protein that comprises a modification in an ECM binding domain of Ang-1, wherein said modification reduces the binding of Ang-1 to an extracellular matrix (ECM) and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a non ECM binding fragment of Ang-1 protein that comprises a modification in an ECM binding domain of Ang-1, wherein said modification reduces the binding of Ang-1 to the (ECM); or~~
- c) a therapeutically effective amount of a ~~proteolytic resistant fragment of Ang-1 protein that comprises a modification in a proteolytic domain of Ang-1, wherein said modification inhibits the proteolysis of Ang-1 and/or a vector comprising a nucleic acid~~

~~molecule that comprises the nucleotide sequence that encodes a proteolytic resistant fragment of Ang-1 protein that comprises a modification in a proteolytic domain of Ang-1, wherein said modification inhibits the proteolysis of Ang-1.~~

2. (Currently amended) The pharmaceutical composition of claim 1 comprising a therapeutically effective amount of an ~~ECM binding extracellular matrix-binding~~ fragment of Ang-1 protein selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and/or and SEQ ID NO:4.

3-18. (Canceled)

19. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 ~~which retain their having angiogenesis promoting activity but which have reduced or inactive ECM binding extracellular matrix-binding, or a homologous peptide thereof or mutant versions of Ang-1 or a homologous peptide thereof and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a mutant Ang-1 which retain their angiogenesis promoting activity but which have reduced or inactive ECM binding or a homologous peptide thereof or mutant versions of Ang-1.~~

20-25. (Canceled)

26. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 ~~which retain their having angiogenesis promoting activity but which is not cleaved into a antagonist fragment, or a~~

~~homologous peptide thereof or a homologous peptide thereof or and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that a mutant Ang-1 which retain their angiogenesis promoting activity but which has is not cleaved into a antagonist fragment or a homologous peptide thereof.~~

27-52. (Canceled)

53. (Currently amended) A pharmaceutical composition comprising
 - a) a pharmaceutically acceptable carrier and
 - b) a therapeutically effective amount of an Ang-1 fragment with antagonist activity, and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of an Ang-1 fragment with antagonist activity.
54. (Currently amended) The pharmaceutical composition of claim 53 further comprising Ang-2 protein, and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of Ang-2.
55. (Original) The pharmaceutical composition of claim 53 comprising a therapeutically effective amount of an Ang-1 fragment with antagonist activity.
56. (Currently amended) The pharmaceutical composition of claim 53 wherein said Ang-1 fragment with antagonist activity comprises an amino acid sequence comprising SEQ ID NO:11 and/or SEQ ID NO:12, and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence encoding for SEQ ID NO:29 and/or SEQ ID NO:30.

57-80. (Canceled)